Defective brain hormonal signaling has been associated with Alzheimer's disease (AD), a disorder characterized by synapse and memory failure. Irisin is an exercise-induced myokine released on cleavage of the membrane-bound precursor protein fibronectin type III domain-containing protein 5 (FNDC5), also expressed in the hippocampus. Here we show that FNDC5/irisin levels are reduced in AD hippocampi and cerebrospinal fluid, and in experimental AD models. Knockdown of brain FNDC5/ irisin impairs long-term potentiation and novel object recognition memory in mice. Conversely, boosting brain levels of FNDC5/ irisin rescues synaptic plasticity and memory in AD mouse models. Peripheral overexpression of FNDC5/irisin rescues memory impairment, whereas blockade of either peripheral or brain FNDC5/irisin attenuates the neuroprotective actions of physical exercise on synaptic plasticity and memory in AD mice. By showing that FNDC5/irisin is an important mediator of the beneficial effects of exercise in AD models, our findings place FNDC5/irisin as a novel agent capable of opposing synapse failure and memory impairment in AD.
T he incidence of AD, the most common form of dementia in older individuals, is increasing as the world population ages, with more than 35 million people now affected worldwide 1 . Currently, there is no effective treatment for AD 2 ; notable efforts are aimed at developing strategies to counteract mechanisms leading to neuronal damage, synapse failure, and memory impairment in AD.
Consolidated evidence indicates that the central nervous system (CNS) is an important target for the actions of peripheral hormones, including insulin, leptin, glucagon-like peptide-1, glucocorticoids, and others [3] [4] [5] . Insulin, leptin, and glucagon-like peptide-1 stimulate neuronal survival and synaptic plasticity, and they contribute to higher brain functions, including cognition [6] [7] [8] [9] . Failure of hormone-initiated signaling pathways has been associated with brain disorders, including AD 10 . For example, brain insulin signaling is decreased in AD 4, [11] [12] [13] , and strategies aimed at bolstering it are currently under clinical investigation 14, 15 .
Irisin was recently identified as a myokine released into the circulation on physical exercise that is capable of stimulating adipocyte browning and thermogenesis in mice and humans 16, 17 . Irisin is cleaved from fibronectin type III domain-containing protein 5 (FNDC5), a transmembrane precursor protein expressed in muscle under the control of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α ). FNDC5/irisin stimulates the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus 18 , a brain region centrally involved in learning and memory. This raises the possibility that FNDC5/irisin could play a neuroprotective role in brain disorders such as AD. In this study, we investigated FNDC5/ irisin levels in the brain and cerebrospinal fluid (CSF) of patients with AD and in mouse models of AD, and we tested the hypothesis that FNDC5/irisin could be a key mediator of the beneficial effects of exercise on synaptic plasticity and memory in AD models, thus holding promise as a potential target for therapeutic intervention in AD.
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Results
Immunodetection of FNDC5/irisin in the brain. Since the original report 16 describing irisin as a cleavage product derived from FNDC5 (Fig. 1a) , the existence and possible physiological functions of irisin in rodents and humans have been a matter of controversy. Part of the debate has focused on the specificity and identity of proteins identified using anti-FNDC5/irisin antibodies. The existence and levels of irisin in human plasma have been settled using state-of-the-art mass spectrometry analysis 17 . Here we initially validated the rabbit polyclonal antibody used in this study (anti-FNDC5; Abcam, catalog no. ab131390) against recombinant irisin produced in Chinese hamster ovary (CHO) cells (AdipoGen; catalog no. AG-40B-0136). In agreement with recent reports 19, 20 , previous incubation of the antibody with antigen at increasing molar ratios effectively blocked immunodetection of recombinant irisin in western blots (Extended Data Fig. 1a ). We note, nonetheless, that because irisin is derived from FNDC5, immunological approaches to detect irisin inherently detect its precursor FNDC5 in samples in which the latter is also present. Moreover, irisin has been reported to exhibit an apparent molecular mass in the 22-32 kDa range resulting from dimerization and/or glycosylation 15, [18] [19] [20] [21] . This is similar to the molecular mass of FNDC5 16, 21 , making it difficult to discriminate between FNDC5 and irisin in immunoblots from tissue samples where both FNDC5 and irisin may be present. Thus, in the current study, we refer to FNDC5/ irisin when describing results based on immunological detection of irisin in brain tissue homogenates. On the other hand, because irisin is thought to comprise the majority of secreted FNDC5/irisin 16 , we refer to irisin when describing results obtained in CSF or plasma using an irisin enzyme-linked immunosorbent assay (ELISA) kit.
We used the anti-FNDC5 antibody to identify FNDC5/irisin in mouse hippocampal ( Fig. 1b ) and human cortical homogenates ( Fig. 1c ). Immunoblots showed a band at 29 kDa, within the range reported for irisin, which migrated with similar electrophoretic mobility as recombinant irisin (CHO cells; Adipogen; catalog no. AG-40B-0136) ( Fig. 1b ). Mass spectrometry analysis in this band identified a peptide with amino acid sequence DNEPNNNK, which is contained within FNDC5 (Extended Data Fig. 1b ,c and Source Data 1). On the basis of mass spectrometry results and because this band (which we termed band 1) was detected at the same apparent molecular mass as recombinant irisin, we used band 1 for quantification of FNDC5/irisin levels in subsequent experiments. In addition, we detected immunopositive bands at apparent molecular masses of ~40, 58, and 75 kDa (bands 2, 3, and 4, respectively; Fig. 1b ). To rule out the possibility that bands 2-4 could reflect nonspecific antibody labeling, we analyzed them by mass spectrometry. The results showed that bands 2 and 3 contained the same FNDC5 peptide as band 1. An additional peptide (DEVTMKEMGR) identified in band 4 was also comprised within FNDC5/irisin (Extended Data Fig. 1b,c and Source Data). The results indicate the presence of different forms of FNDC5/irisin (for example, multimers and/ or posttranslationally modified species) in immunoblots from brain homogenates. FNDC5/irisin is reduced in AD brains and CSF, and in AD experimental models. FNDC5/irisin was significantly reduced in the hippocampi of late-stage AD patients compared to age-matched early AD or cognitively normal individuals ( Fig. 1d ,e; see Supplementary  Table 1 for demographics). No changes were detected in β IIItubulin (Tuj1), used as a neuron-specific control, indicating that the decrease in FNDC5/irisin was not caused by significant neuronal death in the samples analyzed (data not shown).
For CSF analysis of AD or control individuals, we employed an irisin ELISA kit (Phoenix Pharmaceuticals; catalog no. EK-067-29), which robustly recognizes recombinant irisin (Extended Data Fig. 1d ). Irisin was decreased in the CSF of AD patients compared to mild cognitive impairment (MCI) or nondemented controls (Fig. 1f ).
Lewy body dementia (LBD) patients also presented reduced levels of irisin in the CSF (Fig. 1f ). No significant alterations were found in plasma levels of irisin in AD or LBD patients compared to nondemented controls (Fig. 1g ). CSF irisin levels showed a positive correlation with age in non-demented controls, but not in AD patients (Fig. 1h ,i). While we found no correlation between CSF and plasma irisin levels in controls or AD patients (Extended Data Fig. 2a ,b), we found a selective reduction in the CSF/plasma ratio of irisin in AD patients, but not in MCI or LBD patients (Extended Data Fig. 2c ).
Next, we sought to determine whether amyloid-β oligomers (Aβ Os), soluble Aβ aggregates that accumulate in AD brains and are linked to synapse failure and memory loss 2, 22 , impact FNDC5/ irisin levels. Exposure of rat hippocampal cultures to Aβ Os (500 nM; 24 h), reduced FNDC5/irisin at both messenger RNA (mRNA) (Extended Data Fig. 3a ) and protein (Extended Data Fig. 3b ,c) levels. FNDC5/irisin immunoreactivity was mostly associated with the surface of mature neurons (positively labeled for β III-tubulin), with little immunoreactivity present in glial fibrillary acidic protein (GFAP)-positive astrocytes (Extended Data Fig. 3d ,e). FNDC5/irisin immunoreactivity was reduced in Aβ O-exposed hippocampal cultures (Extended Data Fig. 3f ,g). Specificity of surface staining by the anti-FNDC5 antibody was confirmed by our observation that lentivirus-mediated short hairpin RNA (shRNA) knockdown of FNDC5 markedly reduced its surface immunostaining (Extended Data Fig. 3h ). We next exposed cultured human adult cortical slices 23 to Aβ Os (500 nM) for 12 h and observed that mRNA and protein levels of FNDC5/ irisin were reduced ( Fig. 2a-c) .
Consistent with previous reports 18, 24 , we found that FNDC5/irisin is expressed in the hippocampus and cortex of C57BL/6 mice, albeit at lower levels than in skeletal muscle (Extended Data Fig.  4a ). Intracerebroventricular infusion of Aβ Os (10 pmol in a single dose) 25, 26 in C57BL/6 mice caused a significant reduction in hippocampal (Extended Data Fig. 4b,c ), but not in skeletal muscle FNDC5/irisin mRNA (Extended Data Fig. 4d ,e) after 24 h or 7 days. FNDC5/irisin protein levels detected by ELISA were reduced in the hippocampi of mice 24 h post-infusion of Aβ Os (Fig. 2d ). FNDC5/irisin levels were also reduced in the hippocampi of 13-to 16-month-old APPswe/PS1Δ E9 mice (henceforth referred to as APP/PS1 Δ E9) ( Fig. 2e ,f), which develop amyloid pathology and memory deficits 27 . Taken together, our results indicate that FNDC5/ irisin is expressed in the hippocampus and is reduced in AD brains and CSF, as well as in experimental models of AD.
Because FNDC5/irisin levels are controlled by PGC-1α 16 , known to mediate synapse function and neuroprotection 28 , we investigated PGC-1α and peroxisome proliferator-activated receptor gamma (PPAR-γ ) expression in Aβ O-infused mice. Expression of both PGC-1α (Extended Data Fig. 4f ,g) and PPAR-γ (Extended Data Fig.  4h ,i), but not of peroxisome proliferator-activated receptor alpha (Extended Data Fig. 4j ,k), were reduced in mouse hippocampi 24 h and 7 days post-infusion with Aβ Os. PGC-1α protein levels were also reduced 7 days post-infusion (Extended Data Fig. 4l ,m).
Knockdown of brain FNDC5/irisin impairs synaptic plasticity and memory in mice.
We infused C57BL/6 mice intracerebroventricularly with lentiviruses harboring two different shRNA constructs that efficiently knocked down FNDC5 ( Fig. 3a,b ). This resulted in impaired maintenance of hippocampal long-term potentiation (LTP) ( Fig. 3c,d ) and memory in a novel object recognition (NOR) task ( Fig. 3e ). Mice infected with a control lentiviral vector (harboring an shRNA targeting luciferase) exhibited normal performance in the NOR task ( Fig. 3e ). Downregulation of brain FNDC5/irisin had no impact on performance in the radial arm water maze (RAWM) or contextual fear conditioning (CFC) tasks in wild-type mice ( Fig. 3f,g) . Control experiments showed that 
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lentivirus-infected mice showed no significant differences in motor activity or body weight (Extended Data Fig. 5a -c). Thus, results indicate that while brain FNDC5/irisin does not contribute to CFC and RAWM memory, it influences hippocampal synaptic plasticity and NOR memory in C57BL/6 mice.
Boosting brain FNDC5/irisin levels rescues synapse plasticity and memory defects in mouse models of AD. We next observed that recombinant irisin rescued impaired LTP in Aβ O-exposed hippocampal slices ( Fig. 4a,b ). Further, bilateral intrahippocampal infusion of recombinant irisin (75 pmol per site) prevented Aβ O-induced impairment in NOR and fear conditioning memory (Extended Data Fig. 6a ,b). To further explore whether FNDC5/irisin could counteract the direct impact of Aβ Os on memory 25, 26 , C57BL/6 mice were infected intracerebroventricularly with a green fluorescent protein (GFP) control vector (AdGFP) or with AdFNDC5, an adenoviral vector that overexpresses FDNC5. Six days post-infection, mice received a single intracerebroventricular infusion of Aβ Os (or vehicle). Control measurements showed that neither viral infection nor Aβ O infusion caused any changes in speed or distance traveled, or in the time spent at the center or periphery in an open field test (data not shown), indicating lack of effects on locomotor activity and anxiety. Brain expression of FNDC5/irisin blocked the Aβ O-induced alterations on both NOR ( Fig. 4c ) and CFC memory tests ( Fig. 4d ). Infection with AdFNDC5 led to increases in FNDC5/irisin mRNA expression and protein levels in the cortex (Fig. 4e ,f) and hippocampus 6 days post-infection ( Fig. 4g,h) .
We further used a quantitative PCR (qPCR) array to interrogate hippocampal gene expression related to synaptic plasticity in mice previously infected with either AdGFP or AdFNDC5 and subsequently infused with vehicle or Aβ Os. Among 84 genes analyzed, AdFNDC5 rescued Aβ O-induced changes in expression of six genes, whose expression levels were independently validated by qPCR. These genes included immediate early genes (Egr1, Egr4) and genes coding for the protein phosphatase calcineurin (Ppp3ca), neuronal pentraxin 2 (Nptx2), and subunits of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and metabotropic glutamate receptors (Gria2, Grm2) (Extended Data Fig. 7 ), indicating possible protective actions of FNDC5/irisin against aberrant expression of synapse-related genes.
Next, we intracerebroventricularly infused APP/PS1 Δ E9 mice 27 or wild-type mice with the AdFNDC5 vector or with AdGFP as a control and evaluated synaptic plasticity and memory. Fourteen days post-infection, after completion of behavioral experiments, acute hippocampal slices were prepared, and CA3-CA1 synapses were stimulated for LTP induction. While hippocampal slices from APP/PS1 Δ E9 mice infected with AdGFP exhibited impaired LTP ( Fig. 4i ,j), slices from APP/PS1 Δ E9 mice intracerebroventricularly infused with AdFNDC5 presented normal LTP (Fig. 4i ,j). Brain expression of FNDC5/irisin rescued memory impairment in APP/PS1 Δ E9 mice in both RAWM ( Fig. 4k ) and CFC ( Fig. 4l ). Similar results in LTP, RAWM, and CFC were obtained with APP/PS1 M146L mice, another mouse model of AD 29 (Extended Data Fig. 8a-d) . Control experiments showed that brain expression of FNDC5/irisin had no impact on locomotor activity, somatosensory behavior or body weight in APP/PS1 M146L mice (data not shown). Overall, results indicate that expression of FNDC5/irisin rescued hippocampal synaptic plasticity and memory in AD mice. 
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Neuroprotective actions of recombinant irisin in vitro. Because abnormal eukaryotic initiation factor 2α (eIF2α ) phosphorylation and inhibition of protein synthesis have been recently described as key mechanisms driving synapse damage and memory failure in AD models 10, 26, [30] [31] [32] , we examined the effects of recombinant irisin on phosphorylated eIF2α (eIF2α -P) and activating transcription factor 4 (ATF4) levels in cultured primary hippocampal neurons. Irisin prevented Aβ O-induced elevation in eIF2α -P and ATF4 (Extended Data Fig. 9a -c), as well as downregulation of de novo protein synthesis in hippocampal neurons (Extended Data Fig. 9d,e ). Control measurements revealed that total eIF2α immunoreactivity remained unchanged (not shown). We further found that recombinant irisin prevented dendritic spine loss in cultured hippocampal neurons exposed to Aβ Os (Extended Data Fig. 9f,g) . Additional experiments determined that recombinant irisin reduced Aβ O binding to neurons (Extended Data Fig. 9h ,i). Control binding studies revealed no direct interaction between Aβ Os and recombinant irisin (Extended Data Fig. 9j ), ruling out the possibility that blockade of binding to neurons might be caused by sequestration of Aβ Os by recombinant irisin added to the medium. In addition, surface FNDC5/irisin and Aβ Os did not colocalize in dendrites of hippocampal neurons (Extended Data Fig. 9k ). Results further showed that FNDC5/irisin overexpression reduced hippocampal soluble Aβ 42 levels in APP/PS1 M146L mice (Extended Data Fig. 9l ), but not insoluble Aβ 42 in the hippocampus or cortex (Extended Data Fig. 9m -o).
We found that recombinant irisin stimulated the cyclic AMP (cAMP)-protein kinase A (PKA)-cAMP responsive element-binding protein (CREB) pathway in human cortical slices ( Fig. 5a -c), a pathway that plays important roles in memory formation and has been found to be impaired in AD models [33] [34] [35] . Recombinant irisin further increased cAMP and phosphorylated CREB in mouse hippocampal slices ( Fig. 5d,e ). Irisin-induced CREB phosphorylation was abolished by PKA inhibition with myristoylated protein kinase inhibitor (PKI) 14-22, a selective PKA inhibitor ( Fig. 5e ). We also found that PKA activity mediated protection against nuclear translocation of ATF4 induced by Aβ Os (Fig. 5f ,g). Irisin further induced transient phosphorylation of extracellular signalregulated kinase in cultured neurons (data not shown). The effect of recombinant irisin was similar to forskolin, a direct activator of adenylyl cyclase (data not shown). Taken together, these results provide initial clues into the mechanisms by which recombinant irisin affords neuroprotection in experimental models of AD.
FNDC5/irisin mediates the protective actions of physical exercise on synaptic plasticity and memory in AD models. From a translational perspective, physical exercise could be a non-pharmacological strategy to increase hippocampal FNDC5/irisin in patients at (1) shCtrl . Two-sided one-way ANOVA followed by Holm-Šidák correction. Bars express mean ± s.e.m. g, shCtrl or shFNDC5 (1)-infused C57BL/6 mice were assessed in a two-day RAWM task and presented similar error profiles across trials. Each block consisted of three consecutive trials. N = 9 shCtrl, 11 shFNDC5 (1); repeated measures two-way ANOVA. Values are presented as mean ± s.e.m.
Articles
NAturE MEDICINE
risk of developing AD or in patients already exhibiting cognitive impairment. Thus, we initially tested whether a protocol of daily swimming (1 h per day, 5 days per week for 5 weeks) could protect mice from Aβ O-induced memory deficits and reduction in brain levels of FNDC5/irisin. Notably, exercised mice were protected from Aβ O-induced impairment in NOR memory both 24 h (Extended Data Fig. 10a ) and 5 days (Extended Data Fig. 10b ) following Aβ O infusion. Protection against Aβ O-induced memory deficits was also verified in the CFC paradigm (Extended Data Fig. 10c ). We further found that this exercise protocol prevented Aβ O-induced reductions in FNDC5/irisin mRNA (Extended Data Fig. 10d ) and protein (Extended Data Fig. 10e ) in mouse hippocampi. Moreover, consistent with a previous report 18 , hippocampal levels of FNDC5/irisin (Extended Data Fig. 10e ) and BDNF (Extended Data Fig. 10f ,g) were higher in exercised mice compared to sedentary animals.
We then asked whether brain FNDC5/irisin mediated the beneficial effect of physical exercise on synapse plasticity in APP/PS1 Δ E9 mice. We conducted an intracerebroventricular infusion of a lentiviral vector harboring FNDC5 shRNA and subsequently subjected mice to the exercise protocol. Results revealed that exercise improved LTP in APP/PS1 Δ E9 mice infused with an innocuous shRNA (targeting luciferase), but not in APP/PS1 Δ E9 mice exhibiting downregulated brain FNDC5/irisin expression ( Fig. 6a,b) . Additionally, we observed that downregulation of brain FNDC5/ irisin did not exacerbate LTP impairment in sedentary APP/PS1 Δ E9 mice ( Fig. 6a,b ).
We next aimed to determine a potential role of peripheral FNDC5/irisin in the brain. We administered the AdFNDC5 vector into the caudal vein of mice to induce peripheral FNDC5/irisin expression, as previously described 18 . Peripheral administration of AdFNDC5 rescued NOR memory defects in Aβ O-infused mice 
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NAturE MEDICINE ( Fig. 6c ). We next evaluated plasma levels of FNDC5/irisin in this group of mice and found unaltered levels in Aβ O-infused animals ( Fig. 6d ). As expected, plasma levels of FNDC5/irisin were increased in animals that received AdFNDC5 intravenously ( Fig. 6d ). Moreover, while hippocampal levels of FNDC5/irisin were decreased in Aβ O-infused mice, intravenous injection of AdFNDC5 resulted in increased hippocampal FNDC5/irisin levels and prevented the decrease triggered by Aβ Os (Fig. 6e ). These results suggest that peripheral FNDC5/irisin can either reach the brain or trigger an increase in brain FNDC5/irisin. They further demonstrate that peripheral FNDC5/irisin affords protection against Aβ O-induced memory impairment.
Our second approach to investigate the role of peripheral FNDC5/irisin in synaptic plasticity and memory in AD models consisted of neutralizing peripheral FNDC5/irisin. To this end, we carried out intraperitoneal injections of anti-FNDC5 antibodies in either sedentary or exercised Aβ O-infused mice. This approach has been previously described to attenuate irisin-induced expression of pro-thermogenesis genes in mice 16 . Interestingly, intraperitoneal administration of anti-FNDC5 blocked the protective actions of physical exercise against the impairments in synaptic plasticity and memory induced by Aβ Os (Fig. 6f,g) . We further noted that intraperitoneal administration of the anti-FNDC5 antibody per se impaired synaptic plasticity and performance in the NOR test ( Fig. 6f,g) . We next aimed to evaluate the effects of exercise and peripheral administration of anti-FNDC5 on hippocampal FNDC5/ irisin levels. In accordance with the results in Extended Data Fig. 10 , we found that exercise prevented the decrease in hippocampal 
NAturE MEDICINE levels of FNDC5/irisin triggered by Aβ Os (Fig. 6h) . Interestingly, we observed that administration of anti-FNDC5 led to a decrease in hippocampal FNDC5/irisin levels in exercised Aβ O-infused mice (Fig. 6h ). Collectively these results indicate that peripheral irisin may reach the brain and mediate the neuroprotective actions of exercise in synaptic plasticity and memory in AD. Lastly, we tested whether the approach to neutralize peripheral FNDC5/irisin using an anti-FNDC5 antibody would block the beneficial effects of exercise on memory in APP/PS1 Δ E9 mice. Our results showed that peripheral administration of the anti-FNDC5 antibody prevented the protective actions of exercise in APP/PS1 Δ E9 mice in the NOR test ( Fig. 6i ). Collectively, these results importantly demonstrate that FNDC5/irisin mediates the positive effects of exercise on synaptic plasticity and memory.
Discussion
AD is a neurological disorder that primarily affects memory, with no cure to date. A variety of potential underlying mechanisms have been proposed to explain the pathogenesis of AD 10, 36 . Considerable evidence indicates that memory impairment in AD is caused by synapse failure and loss 2,37,38 . Thus, therapies aimed at restoring or preserving synapse function and cognition are highly warranted.
Irisin was originally discovered as an exercise-induced myokine that shifts the adipose metabolism toward a thermogenic profile 16, 39 . There has been some debate as to the nature and identity of FNDC5/ irisin, and to its functional relevance in humans 40 . While concerns have been expressed regarding the lack of specificity of anti-irisin antibodies 41 , sensitive approaches have been successfully employed to confirm the identity of irisin and to measure its circulating levels in humans 17, 20 . Three complementary lines of evidence indicate the specificity of the anti-FNDC5 antibody and ELISA kit used in the current work: (1) FNDC5/irisin levels detected by ELISA showed the expected increase or decrease, respectively, when FNDC5/irisin was overexpressed by use of an adenoviral vector (in both brain and circulation) or when it was knocked down in the brain using a lentiviral vector; (2) surface labeling of FNDC5/irisin by anti-FNDC5 in cultured neurons was predictably reduced in neurons infected by a lentiviral vector harboring shRNA to knock down FNDC5/ irisin; (3) mass spectrometry analysis identified peptides contained within FNDC5 in excised gel bands that were immunolabeled by the anti-FNDC5 antibody. By coupling immunodetection and mass spectrometry, we offer initial evidence that FNDC5/irisin is present in multiple forms with distinct apparent molecular weights in the brain, suggesting it may undergo posttranslational modifications and/or exist in different aggregation states. Indeed, putative glycosylation sites are present in FNDC5/irisin 21 , and previous reports have suggested that shifts in electrophoretic mobility of FNDC5/ irisin are due to glycosylation 16, 20 .
An interesting study demonstrated that FNDC5/irisin is induced via PGC-1α in the mouse brain and promotes BDNF expression 18 . Extending those previous findings and arguing for a physiological role of FNDC5/irisin in the human brain, we show that ex vivo human adult cortical slices express FNDC5/irisin and respond to exogenous recombinant irisin by activating the cAMP-PKA-CREB memory pathway 42 . Our in vitro findings further show that irisin blocks Aβ O binding to neurons and prevents Aβ O-induced eIF2α -P and inhibition of protein synthesis. We and others have recently described these events as essential for synapse and memory failure in AD models, thereby pinpointing a potential downstream pathway by which irisin preserves memory 10, 26, 30 . We note that the cellular receptor(s) for irisin remain(s) to be identified, which limits current knowledge on downstream signaling mechanisms. The identification of the irisin receptor(s) and the detailed signaling mechanisms triggered in the periphery and in the brain are needed in the field.
The reduced brain and CSF levels of FNDC5/irisin in AD patients and in animal models reported in this study support the notion that defective brain hormonal signaling in AD impacts mechanisms related to memory formation and brain function [3] [4] [5] . It is noteworthy that we found a positive correlation between age and CSF irisin in control, non-demented individuals, but not in MCI and AD patients, suggesting that the increase in brain FNDC5/irisin with aging may be part of an endogenous mechanism to cope with the many challenges faced by the aging brain.
Irisin was reduced in the CSF of AD patients, but not in plasma, indicating a specific decrease in the CNS. Our finding that hippocampal FNDC5/irisin is reduced in moderate-to-late AD, but not in MCI, suggests that decreased FNDC5/irisin is not a likely cause of early cognitive impairment in AD, but may contribute to memory 
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defects as disease progresses. Additional studies measuring irisin levels in the CSF during healthy aging and in patients with other neurological disorders are anticipated and will help to determine when irisin levels decrease during the course of AD.
Blockade of either brain or peripheral FNDC5/irisin in mice impaired LTP and NOR memory, implicating FNDC5/irisin in physiological memory processes. However, future studies are warranted to address the precise physiological roles of brain and peripheral FNDC5/irisin in the formation and consolidation of different types of memories.
It is noteworthy that peripheral administration of AdFNDC5 led to increases in hippocampal FNDC5/irisin and protected mice against memory impairment induced by Aβ Os. Most importantly, peripheral FNDC5/irisin is implicated in the preservation of hippocampal FNDC5/irisin levels, synaptic plasticity, and memory in AD mice. Collectively, these results provide mechanistic information on the beneficial actions of FNDC5/irisin in the brain and suggest that a cross talk between peripheral and central FNDC5/irisin influences synaptic plasticity and memory in mice.
Physical exercise has been previously shown to induce memory-related events in the brain [43] [44] [45] and has been proposed as an approach to reduce the risk of AD, potentially bringing about significant benefits to subjects with MCI and early AD [46] [47] [48] [49] . Many efforts to identify the endogenous molecules responsible for the beneficial effects of exercise are underway. Brain PGC-1α and BDNF 28 The results presented in this study add FNDC5/irisin to this list. Our findings suggest that FNDC5/irisin could comprise an attractive novel therapy aimed to prevent dementia in patients at risk, as well as delay its progression in patients at the later stages, including those who can no longer exercise. Many patients with dementia are disabled due to other age-related conditions or comorbidities (for example, arthritis, heart disease, obesity, visual problems, depression) that preclude them from engaging in regular physical exercise. Therefore, the development of alternative approaches that build on the beneficial effects of exercise in the brain may benefit those patients.
In conclusion, our results demonstrate that FNDC5/irisin levels are reduced in human AD brains and CSF and in AD mouse models, and that boosting either brain or peripheral FNDC5/irisin levels attenuates synaptic and memory impairments in AD mouse models. We further show that FNDC5/irisin is a novel mediator of the beneficial effects of exercise on synapse function and memory in AD models. Bolstering brain FNDC5/irisin levels, either pharmacologically or through exercise, may thus constitute a novel therapeutic strategy to protect and/or repair synapse function and prevent cognitive decline in AD.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-018-0275-4. Adenoviral vectors designed to express GFP or FNDC5 (AdGFP or AdFNDC5, respectively) were produced by ViraQuest Inc. using the Gateway expression system (Thermo Fisher Scientific), as described previously 16, 18 , and were kindly donated by Dr. Bruce Spiegelman (Harvard University). High-titer viral particles (1.0 × 10 11 per ml) were diluted and used in the reported experiments. MISSION lentiviral particles targeting luciferase (control) or FNDC5 were obtained from Sigma-Aldrich. , washed 3 times for 10 minutes with tris-buffered saline and Tween (TBST), incubated for 1 h at room temperature with peroxidase-conjugated goat anti-rabbit immunoglobulin G (IgG) secondary antibody (1:50,000 dilution in blocking buffer; Thermo Fisher Scientific), developed using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) and imaged on a Azure c600 (Azure Biosystems) imaging station. The positions of immunolabeled bands in the membranes were used to guide excision of the corresponding bands from unstained separate lanes from the other half of the gel (mirror) that had not been electrotransferred. Excised gel bands were subjected to in-gel digestion as described previously 53 . Commercial recombinant irisin expressed in CHO cells (AdipoGen, catalog no. AG-40B-0136) digested in aqueous solution or digested/eluted from bands excised from an SDS-PAGE gel (run exactly as described earlier) were used as standards. Mass spectrometry analyses were carried out at the Queen's University Mass Spectrometry facility in Kingston, Canada. Samples containing tryptic fragments were analyzed on an Orbitrap Velos Pro (Thermo Fisher Scientific) mass spectrometer coupled to a nano-LC system and nano-electrospray ionization source (Thermo Fischer Scientific). Eluent A was aqueous formic acid (0.1%, v/v) and eluent B was high-performance liquid chromatography-grade acetonitrile containing 0.1% (v/v) formic acid. Samples (10 µ l) were injected by the autosampler onto the trap column (C18, internal diameter 100 µ m, length 20 mm, particle diameter 5 µ m) (CMP Scientific) and were separated on an analysis column (C18, internal diameter 75 µ m, length 100 mm, particle diameter 5 µ m) (CMP Scientific) at a flow rate of 30 nl min −1 using two step gradients, from 5 to 50% eluent B over 70 min to 100% eluent B over 45 min, followed by 100% eluent B for 15 min. The transfer capillary temperature was set to 270 °C. An ion spray voltage of 2.0 kV was applied to a PicoTip on-line nano-electrospray ionization emitter (New Objective). Mass spectrometry scans were acquired at an Orbitrap resolution of 60,000 for an m/z range from 150 to 2,000. Following data acquisition, tandem mass spectrometry spectra were analyzed with Proteome Discoverer 1.4 (Thermo Fischer Scientific) with a precursor mass tolerance of 10 parts per million (ppm) and fragment mass tolerance of 0.8 Da. Alternatively, we manually searched for tandem mass spectrometry spectra corresponding to specific m/z values for peptides identified in recombinant irisin standards in the raw data for samples corresponding to each band excised from the SDS-PAGE gel.
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Nano-liquid chromatography (nano-LC)-linear trap quadropole Orbitrap mass spectrometry analysis of immunodetected FNDC5/irisin in mouse
Ex vivo human cortical slices. Adult human cortical slices were previously characterized and prepared as described previously 23, 54 with minor modifications. Healthy cortical tissue was obtained from patients with drug-resistant temporal lobe epilepsy subjected to surgical interventions for removal of epileptic foci. Donors were two men (aged 37 and 49) and three women (aged 18, 39, and 66). After dissection under sterile conditions, 400-μ m-thick slices were prepared using a McIlwain tissue chopper and plated on Neurobasal-A medium containing 2% B27, 500 μ M glutamine, 5 ng ml −1 FGF2, 2 μ M dehydroepiandrosterone sulfate, 1 ng ml −1 BDNF and 50 μ g ml −1 gentamicin. After 7 days in culture at 37 °C and 5% CO 2 , slices were exposed to Aβ Os (500 nM) or the corresponding volume of vehicle for 12 h and were processed for biochemical analyses thereafter. When present, irisin (25 nM) was added for the indicated time periods and tissue was harvested for subsequent analyses.
Postmortem human brain tissue. For western blotting analyses, brain samples from noncognitively impaired, early or late AD patients (defined by combined pathological and cognitive assessment) were obtained from the University of Kentucky Alzheimer's Disease Center Biobank. Experimental procedures involving human tissue were in compliance with the University of Kentucky Institutional Review Board (IRB). Samples from Brodmann areas 21/22 (superior and midtemporal gyri) were snap frozen at autopsy as previously described. AD tissue was from symptomatic individuals with clinical and pathological features, which are described in Supplementary Table 1 . All patients were categorized by Mini-Mental State Examination as control (26) (27) (28) (29) (30) , early AD (20) (21) (22) (23) (24) (25) , and late AD (13) (14) (15) (16) (17) . Sample groups were separated so as to clearly define differences in content of proteins of interest and Mini-Mental State Examination score.
Human CSF and plasma. CSF or plasma from control and AD patients were collected after extensive neuropsychological investigation supervised by a boardcertified psychiatrist, as described previously 55 . The study cohort included men and women. Age (mean ± s.d.), in years, was distributed as follows: controls (67.5 ± 4.9); MCI (71.5 ± 5.8); AD (72.5 ± 8.1); and LBD (71.6 ± 7.0). CSF was collected by lumbar puncture performed at 9 a.m. in all cases. CSF was centrifuged, aliquoted, and immediately frozen at − 80 °C. Total blood was collected in heparincoated tubes and plasma was isolated by centrifugation. Irisin concentration was determined using a commercial ELISA kit (Phoenix Pharmaceuticals), according to the manufacturer's instructions.
Animals. Male C57BL/6 or Swiss mice were obtained from the animal facility at the Federal University of Rio de Janeiro and were 2.5-3 months old at the beginning of experiments. Male and female APP/PS1 ∆ E9 mice on a C57BL/6 background 27 were originally obtained from The Jackson Laboratories and bred at our animal facility. Male and female double transgenic mice (APP/PS1 M146L) were obtained by crossing Tg2576 mice harboring mutant human APP (K670M:N671L) with mutant PS1 (M146L) mice 29 . Wild-type littermates were used as controls. All animals had their genotypes confirmed before use. Animals were housed in groups of five per cage with free access to food and water, under a 12 h light-dark cycle, with controlled room temperature and humidity. Experiments using C57BL/6 mice are presented in the main text, while biochemical and behavioral experiments in Swiss mice performed to validate and confirm our findings are presented as Extended Data Figures. All procedures followed the Principles of Laboratory Animal Care formulated by the US National Institutes of Health.
Brain infusions in mice. For intracerebroventricular infusion of Aβ Os, mice were anesthetized with 2.5% isoflurane (Cristália) using a vaporizer system (Norwell) and were gently restrained only during the injection procedure, as described previously 25, 56 . A 2.5-mm-long needle was unilaterally inserted 1 mm to the right of the midline point equidistant from each eye and 1 mm posterior to a line drawn through the anterior base of the eye 25, 26, 56, 57 ; 10 pmol Aβ Os (or vehicle) was injected in a final volume of 3 μ l and the needle was kept in place for an additional 30 s to prevent backflow. Mice that showed signs of misplaced injections or any sign of hemorrhage were excluded from further analysis. Recombinant irisin (75 pmol per site) was bilaterally delivered into the hippocampal CA1 region (stereotaxical coordinates relative to bregma: 2.0 mm anteroposterior, ± 1.5 mm mediolateral, 1.5 mm dorsoventral), immediately before Aβ O injections. Adenoviral particles (1 × 10 8 ) harboring GFP (AdGFP) or FNDC5 (AdFNDC5) constructs were stereotaxically injected into the right lateral ventricle of wild-type C57BL/6 or APP/PS1 mice (coordinates relative to bregma: 0.2 mm anteroposterior; 1.0 mediolateral; 2.4 mm dorsoventral). Injections were performed in a volume of 2 μ l infused over 30 s. Behavioral studies were carried out at least 6 days postinjection. Lentiviral particles expressing shRNA against murine FNDC5 or luciferase (control) were injected intracerebroventricularly as described earlier. Lentiviruses (titer of 1.0-2.0 × 10 9 particles per ml) were injected in a volume of 3 μ l per animal. Behavioral and electrophysiological studies were carried out four weeks post-injections. Six days before the Aβ O infusions, AdFNDC5 or AdGFP (100 μ l; 10 6 particles per μ l) were injected intravenously into the caudal vein in mice anesthetized with isoflurane (2.5%) and gently restrained during the procedure.
Aerobic exercise in mice. Swiss mice were adapted to swimming for 10 min each day for 2 days to reduce water-induced stress. The duration of exercise was gradually increased until mice swam for 60 min, which was reached, on average, Articles NAturE MEDICINE on the fifth day of training. Exercise sessions were performed during the light cycle and consisted of 60 min swimming sessions, 5 days per week for 5 weeks. Mice swam in groups of four in plastic barrels (60 cm depth × 45 cm diameter). Water temperature was maintained at ~24 °C. On the fifth week of training, animals were injected intracerebroventricularly with Aβ Os (10 pmol) and the NOR task was performed 24 h or 5 days post-injection of Aβ Os. CFC was performed 6-7 days post-injection. Animals were killed by decapitation 1 h after the last test session. Since C57BL/6 are smaller than Swiss mice and less resistant to long exercise sessions, we adapted the protocol when using C57BL/6 mice. In a set of experiments, wild-type or APP/PS1 Δ E9 mice on a C57BL/6 background swam for 20 min for 3 weeks in groups of 4 before LTP recordings. In some experiments, wild-type C57BL/6 mice underwent exercise and were injected intraperitoneally with anti-FNDC5 antibody or control IgG (5 μ g) after the last two exercise sessions, and/or were infused intracerebroventricularly with Aβ Os (10 pmol) in the last exercise session. Mice were assessed in the NOR test 24 h after oligomer injections. Alternatively, in experiments aimed at testing NOR memory, wild-type or APP/PS1 Δ E9 mice were subjected to daily swimming sessions for 1 week, and were injected intraperitoneally with anti-FNDC5 antibody or nonspecific IgG (5 μ g) on the first, fourth, and seventh day. NOR was performed 24 h after the last exercise session.
Behavioral testing. NOR. Object recognition tests were carried out in an open field arena measuring 0.3 × 0.3 × 0.45 m 3 , as described previously 25, 26 . Total distance and velocity during the 5-minute open field session were recorded as measures of locomotor activity; no differences were found among the groups. Animals were trained in a 5-min-long session during which they were placed at the center of the arena in the presence of two identical objects. Exploratory behavior (amount of time exploring each object) was recorded by trained researchers. One hour after training, animals were reinserted into the arena for the test session, in which one of the objects had been replaced by a different (novel) object. Again, the amount of time spent exploring familiar and novel objects was measured. Animals that had a total exploration time below 8 s were excluded from the NOR tests. Results are expressed as the percentage of time exploring each object during the training or test session, and were analyzed using a one-sample Student's t-test comparing the mean exploration time for each object with the fixed value of 50% (chance level).
CFC. CFC was evaluated as described previously 26, 58 . For experiments in APP/ PS1 mice, animals were allowed to freely explore the conditioning chamber (0.4 × 0.25 × 0.3 m 3 ) for 2 min, after which a 2-s shock stimulus (0.8 mA) was applied to the floor. Animals remained in the cage for an additional 1 min. After 24 h, mice were placed in the same cage and allowed to explore it for 5 min in the absence of an electric shock. Freezing events were recorded during this period; the percentage of time in freezing behavior was calculated for each animal using the Ethovision software (Noldus Information Technology). In experiments with Aβ O-injected mice and corresponding controls, animals were allowed to freely explore the training chamber (0.25 × 0.25 × 0.25 m 3 ; Harvard Apparatus) for 3 min, after which they received two 2-s-long 0.35 mA foot shocks with a 30 s interval. Animals were removed from the cage after 30 s. Twenty-four hours thereafter, they were reinserted into the box for 5 min and the total freezing time during the test session was determined. The statistical significance of differences between groups was evaluated using a two-way ANOVA followed by Holm-Šidák post-hoc test. After completion of the fear conditioning experiments, animals were subjected to sensory threshold assessment to investigate potentially different susceptibilities to shock; no significant differences in sensory response were found among experimental groups.
Two-day RAWM. RAWM was performed in APP/PS1 mice as described previously 59 . Briefly, mice were tested for their ability to find a platform located in a defined arm of a 6-arm maze along 30 trials in 2 days. On day 1, five training blocks were performed with alternation between visible and hidden platform. On day 2, all five blocks had the platform hidden. A training block comprises 3 trials of 60 s each. The number of entries into incorrect maze arms (errors) was recorded for each session and the number of errors per block was averaged. Visual and motor abilities were assessed by recording swimming velocity and latency to reach a visible platform in an open swimming pool task. Animal tracking in visible platform experiments was automatically performed with the Ethovision software.
Open field. Control experiments to assess locomotor and exploratory activity were performed in the same boxes as the NOR experiments, in which mice were allowed to freely move for 5 min. Total distance, mean velocity, and percentage of time in the center or periphery were recorded and quantified using the ANY-maze software (Stoelting Co.).
LTP measurements.
Mice were killed by cervical dislocation followed by decapitation; their hippocampi were immediately removed. Transverse hippocampal slices (400 μ m) were cut, placed on infusion chambers on artificial CSF (aCSF; 124 mM NaCl, 4.4 mM KCl, 1 mM Na 2 HPO 4 , 25 mM NaHCO 3 , 2 mM MgCl 2 , 2 mM CaCl 2 , 10 mM glucose) and allowed to recover for 90-120 min. For experiments with recombinant irisin and/or Aβ Os in slices from wild-type mice, Aβ Os (200 nM) and/or recombinant irisin (25 nM) were diluted in aCSF and perfused for 20 min before stimulus. For experiments with exercised mice that received anti-FNDC5 (or control IgG), animals were exercised for three sessions and received an intraperitoneal injection of anti-FNDC5 antibody (or nonspecific IgG) after each session. An additional anti-FNDC5 injection was performed before slice preparation and perfusion with Aβ Os or vehicle. For experiments with adenovirus-mediated FNDC5 expression, wild-type or APP/PS1 Δ E9 mice were injected intracerebroventricularly with AdGFP (control) or AdFNDC5 14 days before being killed and slice preparation. Field EPSPs were recorded from the hippocampal CA1 region according to established procedures 34, 60 .
AβOs. Oligomers were prepared from synthetic Aβ 1-42 and were routinely characterized by size-exclusion chromatography, as described previously 23, 25, 61, 62 . For the electrophysiology experiments in hippocampal slices, oligomers were prepared as previously reported 60, 63 and perfused at a final concentration of 200 nM in aCSF.
Mature hippocampal cultures.
Primary rat hippocampal neuronal cultures were maintained in Neurobasal medium supplemented with B27 (Thermo Fisher Scientific), glutamine, and antibiotics according to established procedures 11, 26, 64 , and were used after 18-21 days in vitro. Cultures were exposed to 500 nM Aβ Os or an equivalent volume of vehicle (2% DMSO in PBS) for the time intervals indicated in each experiment. When present, lentiviral vectors targeting FNDC5 (10 6 ml −1 ) were allowed to express for 5 days before cells were processed for immunocytochemistry. When present, recombinant irisin (25 nM) or forskolin (10 μ M) was added to cultures 15 min before Aβ Os, and myristoylated PKI 14-22 (1 μ M) was added 40 min before irisin.
Immunofluorescence. Cells were fixed in ice-cold 4% formaldehyde plus 4% sucrose for 10 min. Aβ O-sensitive (NU4 monoclonal antibody 65 ) and FNDC5 immunolabeling were performed under non-permeabilizing conditions, while cells labeled for eIF2α -P (1:400), total eIF2α (1ː400), GFAP (1:500), β III-tubulin (1:500), or ATF4 (1:400) were permeabilized in 0.1% Triton X-100 for 5 min before primary antibody incubation, followed by Alexa-conjugated secondary antibodies (Thermo Fisher Scientific). Nuclei were counterstained in DAPIcontaining ProLong antifade mounting solution. Coverslips were imaged on a ZEISS AxioObserver Z1 microscope. FNDC5, eIF2α -P, total eIF2α , and ATF4 immunofluorescence intensities were each analyzed in at least 3 experiments (see figure legends) using independent neuronal cultures and Aβ O preparations. In each experiment, 20-30 images (from 2-3 coverslips) were acquired from each experimental condition. Histogram analysis of fluorescence at each pixel across the images was performed using Image J (National Institutes of Health) 66 , as described previously 26 . When indicated, cell bodies were digitally removed from the images so that only immunostaining on dendritic processes was quantified. The statistical significance of differences between experimental groups was assessed with an ANOVA followed by a post-hoc Holm-Šidák test; P values are indicated in the figure legends.
Spine density. After treatments, hippocampal neuronal cultures were fixed in ice-cold 4% formaldehyde plus 4% sucrose for 10 min and permeabilized in 0.1% Triton X-100 for 5 min. Cells were then blocked in 3% bovine serum albumin (BSA) for 1 h and stained with Alexa-conjugated phalloidin (2 U per coverslip), which labels F-actin, in 3% BSA for 2 h at room temperature. Coverslips were mounted in DAPI-containing ProLong Gold antifade mountant and stored in a dark and humid chamber overnight. Coverslips were imaged on a ZEISS AxioObserver Z1 microscope. Images were obtained from at least two coverslips per experimental condition for each experiment (three experiments with independent neuronal cultures). Two or three distal dendrite segments were isolated per neuron, and a researcher blind to experimental conditions manually determined the number of spines. Results are expressed as the mean number of spines per μ m.
RNA extraction and quantitative RT-PCR. Total RNA was extracted from cultures or animal tissues using SV Total RNA Isolation System (Promega), following the manufacturer's instructions. The purity and integrity of RNA preparations were checked using the 260/280 nm absorbance ratio. Only preparations with 260/280 nm absorbance ratios higher than 1.8 and no signs of RNA degradation were used. RNA concentrations were determined by absorption at 260 nm. For real-time quantitative reverse transcription PCR (qRT-PCR), 1 μ g of total RNA was used for complementary DNA (cDNA) synthesis using the High Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific). Quantitative expression analysis of target genes was performed on a 7500 Fast Real-Time PCR system (Thermo Fisher Scientific) with the Power SYBR Green PCR Master Mix. β -Actin (actb) was used as an endogenous reference gene for data normalization. qRT-PCR was performed in 20 µ l reaction volumes according to the manufacturer's protocols. Primer sequences are described in Supplementary  Table 2 . Cycle threshold (C T ) values were used to calculate fold changes in gene expression using the 2 -∆∆C T method 67 . The statistical significance of changes in expression was assessed using a Student's t-test or two-way ANOVA, as indicated in the figure legends. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted accompanying this paper. Additional data that support the findings of this study are available from the corresponding author upon reasonable request. Requests of datasets obtained from human research will be subject to additional reviews steps by the Institutional Review Board who has granted permit for a particular research. Please contact the corresponding authors for additional information.
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Sample size
Sample size for each experiment was estimated by performing pilot studies and by previous experience with different experiments. The rationale was to obtain robust measurements according to the type of experiment, taking variability into consideration. For some experiments, power analyses were performed prior to the start.
Data exclusions In NOR tests, animals were excluded from the analyses if they had less than 8s of total exploration in the training or the testing phase. This was pre-established. No other exclusion criteria was employed in animal studies.
Replication
Studies involved replication of experimental findings whenever possible. Behavioral tests were performed in different cohorts of animals. Culture experiments were performed independent cultures. We did not have failed replications in the experiments presented in this study.
Randomization No algorithm or software was used to randomize animal subjects. Animals were randomly assigned to groups by trained researchers performing each experiment.
Blinding
Experiments involving image analyses, electrophysiology, and behavioral tests in mice were performed in blinded fashion.
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Validation
Antibodies were used according to manufacturer's instructions. Antibody validation for the species/application can be found at the suppliers' webpage. Additional validation for the anti-FNDC5 antibody by immunoblotting and mass spectrometry is present in Extended Data Figure 1 and in Source Data.
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Laboratory animals
This work involved use of 3-month old male WT C57BL/6 or Swiss mice, as reported in each figure. In experiments involving transgenic APP/PS1 mice (on a C57BL/6 background) , both males and females were used, and were aged 6-13 month-old.
Wild animals
This study did not involve wild animals.
Field-collected samples
This study did not involve samples collected from field research.
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Population characteristics
Healthy cortical tissue was obtained from patients with drug-resistant temporal lobe epilepsy subjected to surgical interventions for removal of epileptic foci. Donors were two males (aged 37 and 49 year-old) and three female (aged 18, 39 and 66 year-old). AD tissue was from symptomatic individuals with clinical and pathological features described in Supplementary Table 1 . All subjects were categorized by MMSE as control (26) (27) (28) (29) (30) , early AD (20) (21) (22) (23) (24) (25) , and late AD (13) (14) (15) (16) (17) . Sample groups were separated so as to clearly define differences in content of proteins of interest and MMSE score. Cerebrospinal fluid (CSF) or plasma from control and AD patients was collected after extensive neuropsychological investigation supervised by a board-certified psychiatrist, as described. The study cohort included males and females. Age (mean ± SD), in years, was distributed as follows: Controls (67.5 ± 4.9), MCI (71.5 ± 5.8), AD (72.5 ± 8.1), and LBD (71.6 ± 7.0).
Recruitment
For the CSF study, patients were recruted by the IDOR memory clinic after subjective memory complaints, as reported in Methods. For the ex vivo human cortical slices, patients were subjected to lobectomy after extensive clinical examination and explicit diagnosis of refractory epilepsy by board-certified neurologists at the University Hospital. Brain tissue would be otherwise discarded. All studies are in compliance with local and international regulations, and were approved by competent ethics committees. In all cases, diagnosis was defined by board-certified neurology committees, and there is no anticipated potential bias during selection.
